Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06732895 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.

Study acronym: teACH
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: Ascendis Pharma A/S to Ascendis Pharma A/S Show 6 more changesShow less
    • Enrollment closed, study ongoing
    • Enrollment target: estimated 24 to confirmed 25
    • Primary completion date: Aug 2027 to Sep 2027
    • Study completion date: Sep 2027 to Oct 2027
    • Eligibility criteria expanded, about 36 words
    • Site details revised at 5 of 5 sites
  2. Primary completion date: Dec 2026 to Aug 2027
    • Study completion date: Jan 2027 to Sep 2027
    v5
  3. Study sites: 4 to 5v4
  4. Study sites: 2 to 4v3
  5. Study sites: 1 to 2v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this clinical trial is to evaluate efficacy and safety of once weekly subcutaneous (SC) doses of navepegritide 100 μg/kg compared to placebo (inactive drug) in adolescents aged 12 to 18 years with Achondroplasia. What will be measured is Annualized Growth Velocity after a 52-week treatment period.
Trial Details
NCT Number NCT06732895
Lead Sponsor Ascendis Pharma A/S
Conditions
(from sponsor)		 Achondroplasia
Related terms Achondroplasia
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov